The conversation discusses skepticism about the effectiveness and formulation of a $10 RU58841 gel from a Korean brand, questioning if ethanol is used to hold the active compounds. Concerns are raised about the feasibility of selling it at such a low price.
The user is using topical dutasteride, finasteride, minoxidil, and tretinoin but seeing no results or side effects. They also microneedle every two weeks but experience little bleeding, questioning if a thick scalp is preventing treatment effectiveness.
The group buy for CB-03-01, a topical anti-androgen for hair loss, was postponed and refunded due to issues with the product's form and solubility. The product, also known as Breezula, is an alternative to finasteride with fewer side effects, but its official release is delayed until 2021.
The user improved their hair loss from a Norwood scale 2.5/3 to 1.5/2 using treatments including 2.5 mg dutasteride, RU58841, 15 mg oral minoxidil, isoflavones, NAC, pumpkin seed oil, NAD+, and Vipelin, but still experiences temple recession. Other users expressed concern over the high dosages of oral minoxidil and dutasteride.
High cost of studying 3α-Hydroxysteroid dehydrogenase in hair loss led to suggestions of crowdfunding for research. Users discussed using Procyanidin B2/melatonin topical treatment and tracking funds with blockchain.
PP405 is a medicine, and Google Ventures is funding its development based on evidence from each phase, unlike their investment in Juicero, which was a trend-based gamble. Investing in medicine is a calculated risk, not reliant on being "cool."
Autologous exosome treatment for hair loss is being discussed as an emerging option. Minoxidil, finasteride, and RU58841 are also mentioned as treatments.
Using a blunt tip syringe for applying hair loss treatments like Minoxidil provides better scalp coverage than droppers. Users discuss the benefits of liquid over foam and share tips for effective application.
Eucapil, containing fluridil, is used for hair loss but has impractical packaging. Some users find it effective for maintenance, while others suggest alternatives like anageninc with pyrilutamide.
The conversation discusses the differences in inactive ingredients between Sandoz 5mg Finasteride and Proscar/Propecia, questioning the purpose of certain additives like Docusate sodium. It seeks to determine if these differences affect the effectiveness of the treatment for hair loss.
User shares 8-month progress using Fin/Min/Niz and microneedling for hair loss, with positive results and no side effects. Discusses routine, including Fin 1mg daily, Minox 2x daily, Niz 2x weekly, and derma pen 1.5mm weekly.
The conversation discusses the sale of a premixed KY19382 solution for research purposes, highlighting previous unsuccessful group buys and the formulation process. Prices and purchasing options for KY19382 solutions and powder are provided.
The user reports some hair regrowth after two months of using 1.5mm microneedling with Minoxidil and Nizoral shampoo. They note reduced pain and skin flaking, attributing changes to skin thickening and collagen induction.
The user is considering using CB or clascoterone for hair loss, potentially as an alternative to RU. They're also contemplating asking a dermatologist for topical clascoterone cream to apply to their temple.
A new stem cell method for culturing hair follicles is being developed as an alternative to Minoxidil, finasteride, and RU58841. There are concerns about its cost and accessibility despite plans for commercialization.
The conversation is about using a DIY topical Cetirizine 1% solution with microneedling for hair loss treatment. Concerns were raised about potential side effects and the effectiveness of Cetirizine for this purpose.
The user reported progress in hair loss treatment using oral finasteride, keto 2% shampoo, and vitamin D. They experienced reduced hair fall, fewer scalp issues, and hope for improved hair density.
The conversation discusses using topical Calcipotriol and Valproic Acid for hair loss, focusing on their mechanisms involving the VDR receptor and Wnt/beta-catenin pathway. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.
VDPHL-01 is essentially a slow-release oral minoxidil, which is already known to work for hair growth. The formulation includes other ingredients like Medrogestone, Valproic acid, Setipiprant, and Cetirizine, but their effectiveness and necessity are questioned.
Vitamin C mixed with shampoo stopped shedding and promoted hair regrowth after 1.5 years. Both the person and their wife experienced significant hair loss reduction with this method.
Setipiprant and bimatoprost are being discussed as potential future treatments for hair loss. Some individuals have started testing setipiprant before FDA approval, but no progress updates are available yet.
A user is concerned about hair loss and acne from a one-week course of 70 mg/day oral prednisolone for severe tinnitus. They are asking if these side effects are common.
A 34-year-old man experienced hair loss during the COVID-19 pandemic and successfully treated it using minoxidil, reducing shampoo use, and taking fenugreek. He saw significant improvement within a few months and no longer appears bald.
Stemson Therapeutics will start human trials for hair cloning in late 2025-2026. Product development is complete, and they are preparing for production and clinical trials.
Microneedling aftercare involves using saline water instead of sea water, and avoiding hyaluronic acid due to its potential pro-inflammatory effects. Users suggest using jojoba oil as a carrier for essential oils like rosemary and lavender, and combining microneedling with minoxidil for better hair regrowth results.
The user experienced hair regrowth using 0.5mg oral finasteride and the iRestore laser cap every other day, with reduced shedding. They also take collagen peptides and Nutrafol vitamins, though they are unsure of the latter's effectiveness.
Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.